SCHEMBL20046815

SCHEMBL20046815

CCc1ncc(-c2ccc(-c3ccc(-c4cnc(C(C)C)n4C)cc3)cc2)n1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
GAA P10253 4/20 0.38
TP53 P04637 3/20 0.38
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPK1 P28482 2/20 0.36
USP2 O75604 1/20 0.36
ATP1A1 P05023 6/20 0.36
ATP1B1 P05026 6/20 0.36
ATP1A3 P13637 6/20 0.36
ATP1B2 P14415 6/20 0.36
ATP1A2 P50993 6/20 0.36
ATP1B3 P54709 6/20 0.36
FXYD2 P54710 6/20 0.36
ATP1A4 Q13733 6/20 0.36
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22692182 0.87 LMNA (0.45) MAPTKMT2AMEN1GAATP53
SCHEMBL23483078 0.81 MAPT (0.50) MAPTKMT2AMEN1GAATP53
SCHEMBL20046490 0.81 LMNA (0.55) MAPTKMT2AMEN1GAATP53
SCHEMBL23483079 0.81 MAPT (0.42) MAPTKMT2AMEN1GAATP53
SCHEMBL20075874 0.80 MAPT (0.40) MAPTKMT2AMEN1GAATP53
SCHEMBL24197722 0.78 GAA (0.50) KMT2AMEN1GAATP53LMNA
SCHEMBL27217087 0.77 CYP1A2 (0.58) KMT2AGAALMNASMN1; SMN2ATP1A1
SCHEMBL10272617 0.77 CYP1A2 (0.58) MAPTKMT2AMEN1GAATP53
SCHEMBL20046484 0.77 LMNA (0.44) MAPTKMT2AMEN1GAATP53
SCHEMBL22964379 0.76 LMNA (0.38) MAPTKMT2AMEN1GAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN MAPT 2970/4885KMT2A 1478/4885MEN1 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.